GB202000934D0 - Engineered immune cells - Google Patents
Engineered immune cellsInfo
- Publication number
- GB202000934D0 GB202000934D0 GBGB2000934.6A GB202000934A GB202000934D0 GB 202000934 D0 GB202000934 D0 GB 202000934D0 GB 202000934 A GB202000934 A GB 202000934A GB 202000934 D0 GB202000934 D0 GB 202000934D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- immune cells
- engineered immune
- engineered
- cells
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000002865 immune cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2000934.6A GB202000934D0 (en) | 2020-01-22 | 2020-01-22 | Engineered immune cells |
AU2021211185A AU2021211185A1 (en) | 2020-01-22 | 2021-01-21 | Engineered immune cells |
CA3165473A CA3165473A1 (en) | 2020-01-22 | 2021-01-21 | Engineered immune cells |
US17/759,222 US20230049025A1 (en) | 2020-01-22 | 2021-01-21 | Engineered immune cells |
PCT/GB2021/050128 WO2021148788A1 (en) | 2020-01-22 | 2021-01-21 | Engineered immune cells |
CN202180022834.0A CN115315270A (en) | 2020-01-22 | 2021-01-21 | Engineered immune cells |
EP21701588.2A EP4093431A1 (en) | 2020-01-22 | 2021-01-21 | Engineered immune cells |
JP2022544061A JP2023510958A (en) | 2020-01-22 | 2021-01-21 | engineered immune cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2000934.6A GB202000934D0 (en) | 2020-01-22 | 2020-01-22 | Engineered immune cells |
Publications (1)
Publication Number | Publication Date |
---|---|
GB202000934D0 true GB202000934D0 (en) | 2020-03-04 |
Family
ID=69636913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2000934.6A Ceased GB202000934D0 (en) | 2020-01-22 | 2020-01-22 | Engineered immune cells |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230049025A1 (en) |
EP (1) | EP4093431A1 (en) |
JP (1) | JP2023510958A (en) |
CN (1) | CN115315270A (en) |
AU (1) | AU2021211185A1 (en) |
CA (1) | CA3165473A1 (en) |
GB (1) | GB202000934D0 (en) |
WO (1) | WO2021148788A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202204272D0 (en) * | 2022-03-25 | 2022-05-11 | Ucl Business Ltd | Method for engineering innate-like lymphocytes |
WO2024112866A1 (en) * | 2022-11-22 | 2024-05-30 | Expression Therapeutics, Llc | Engineered t cells |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
WO1991016024A1 (en) | 1990-04-19 | 1991-10-31 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11352439B2 (en) * | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
-
2020
- 2020-01-22 GB GBGB2000934.6A patent/GB202000934D0/en not_active Ceased
-
2021
- 2021-01-21 EP EP21701588.2A patent/EP4093431A1/en active Pending
- 2021-01-21 AU AU2021211185A patent/AU2021211185A1/en active Pending
- 2021-01-21 CN CN202180022834.0A patent/CN115315270A/en active Pending
- 2021-01-21 JP JP2022544061A patent/JP2023510958A/en active Pending
- 2021-01-21 WO PCT/GB2021/050128 patent/WO2021148788A1/en unknown
- 2021-01-21 CA CA3165473A patent/CA3165473A1/en active Pending
- 2021-01-21 US US17/759,222 patent/US20230049025A1/en active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
WO1991016024A1 (en) | 1990-04-19 | 1991-10-31 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
Non-Patent Citations (20)
Title |
---|
AHMAD ET AL., CANCER RES., vol. 52, 1992, pages 4817 - 4820 |
ALABI ET AL., PROC NATL ACAD SCI USA., vol. 110, no. 32, 6 August 2013 (2013-08-06), pages 12881 - 6 |
B. PHILIPE. KOKALAKIL. MEKKAOUIS. THOMASK. STRAATHOFB. FLUTTERV. MARINT. MARAFIOTIR. CHAKRAVERTYD. LINCH: "A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy", BLOOD, vol. 124, 2014, pages 1277 - 1287 |
BLAESE ET AL., CANCER GENE THER., vol. 2, 1995, pages 291 - 297 |
CRYSTAL, SCIENCE, vol. 270, 1995, pages 404 - 410 |
GAO ET AL., GENE THERAPY, vol. 2, 1995, pages 710 - 722 |
I. RIVIEREK. BROSER. C. MULLIGAN: "Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells", PROC. NATL. ACAD. SCI. U.S.A., vol. 92, 1995, pages 6733 - 6737, XP002202961, DOI: 10.1073/pnas.92.15.6733 |
JIANG ET AL., NANO LETT., vol. 13, no. 3, 13 March 2013 (2013-03-13), pages 1059 - 64 |
KARAGIANNIS ET AL., ACS NANO, vol. 6, no. 10, 23 October 2012 (2012-10-23), pages 8484 - 7 |
KAZUKI ET AL., MOL. THER., vol. 19, no. 9, 2011, pages 1591 - 1601 |
KOUPRINA ET AL., EXPERT OPINION ON DRUG DELIVERY, vol. 11, no. 4, 2014, pages 517 - 535 |
LEE ET AL., NAT NANOTECHNOL., vol. 7, no. 6, 3 June 2012 (2012-06-03), pages 389 - 93 |
LI ET AL., CLINICAL CANCER RESEARCH, vol. 23, no. 22, November 2017 (2017-11-01), pages 6982 - 6992 |
MOSSNER E ET AL.: "Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity", BLOOD, vol. 115, no. 22, 2010, pages 4393 - 4402, XP055190313, DOI: 10.1182/blood-2009-06-225979 |
NEWICK ET AL., CANCER IMMUNOL RES, vol. 4, no. 6, June 2016 (2016-06-01), pages 541 - 551 |
RAFIQ ET AL., NATURE BIOTECHNOLOGY, vol. 36, no. 9, 13 August 2018 (2018-08-13), pages 847 - 856 |
REMY ET AL., BIOCONJUGATE CHEM., vol. 5, 1994, pages 647 - 654 |
WANG ET AL.: "2018 IgG Fc engineering to modulate antibody effector functions", PROTEIN CELL, vol. 9, no. 1, January 2018 (2018-01-01), pages 63 - 73, XP055457296, DOI: 10.1007/s13238-017-0473-8 |
WHITEHEAD ET AL., ACS NANO, vol. 6, no. 8, 28 August 2012 (2012-08-28), pages 6922 - 9 |
ZHANG ET AL., ADV MATER., vol. 25, no. 33, 6 September 2013 (2013-09-06), pages 4641 - 5 |
Also Published As
Publication number | Publication date |
---|---|
AU2021211185A1 (en) | 2022-08-04 |
CN115315270A (en) | 2022-11-08 |
CA3165473A1 (en) | 2021-07-29 |
WO2021148788A1 (en) | 2021-07-29 |
EP4093431A1 (en) | 2022-11-30 |
JP2023510958A (en) | 2023-03-15 |
US20230049025A1 (en) | 2023-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277611A (en) | Engineered immune effector cells and use thereof | |
IL282092B (en) | Engineered enzymes | |
SG11202112536UA (en) | Engineered immune cells comprising a recognition molecule | |
EP3964238A4 (en) | Bcma-targeting engineered immune cell and use thereof | |
SG11202111679XA (en) | Engineered cells and uses thereof | |
SG11202011392VA (en) | Genetically engineered cell and application thereof | |
SG11202008731XA (en) | Engineered cells and uses thereof | |
IL299911A (en) | Improving immune cell function | |
IL287777A (en) | Engineered t cells | |
SG11202111515TA (en) | Ebv-specific immune cells | |
EP4148125A4 (en) | Engineered immune cell for allotransplantation | |
GB202000934D0 (en) | Engineered immune cells | |
GB202007321D0 (en) | T cells | |
SG11202108740UA (en) | Engineered immune cells | |
GB202118201D0 (en) | Engineered immune cell | |
GB201915359D0 (en) | Engineered regulatory t cell | |
GB201914611D0 (en) | Engineered immune cell | |
GB202108184D0 (en) | Engineered immune cell | |
GB202208605D0 (en) | Engineered immune cells | |
EP4021465A4 (en) | Engineered immune cells | |
IL304559A (en) | Self-polarizing immune cells | |
GB201912515D0 (en) | Engineered regulatory T cell | |
GB202016372D0 (en) | Genetically engineered microorganisims | |
GB202205572D0 (en) | Engineered T cells | |
GB202204386D0 (en) | Engineered immune cell platform |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |